# Adaptimmune Therapeutics PLC: financial statements, quarterly

ADAPY · OTC · CIK 1621227 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adapy.md) · [Financials](/companies/adapy/financials.md) · [Filings](/companies/adapy/filings.md) · [Insiders](/companies/adapy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adapy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.0](/filings/0001558370-23-018265.md) | [11.0 d](/filings/0001558370-25-003544.md) | [47.6](/filings/0001558370-24-008287.md) | [5.1](/filings/0001558370-24-011798.md) | [7.3](/filings/0001558370-24-015532.md) | [0.2 d](/filings/0001558370-25-003544.md) | [5.7](/filings/0001558370-25-007571.md) | [128](/filings/0001558370-25-011307.md) | [40.9](/filings/0001558370-24-015532.md) | [3.2 d](/filings/0001558370-25-003544.md) | [7.3](/filings/0001558370-25-007571.md) | [13.7](/filings/0001558370-25-011307.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.9](/filings/0001558370-25-007571.md) | [2.5](/filings/0001558370-25-011307.md) |
| Research and development | $m | [33.2](/filings/0001558370-23-018265.md) | [23.1 d](/filings/0001558370-25-003544.md) | [25.5](/filings/0001558370-24-008287.md) | [30.0](/filings/0001558370-24-011798.md) | [37.8](/filings/0001558370-24-015532.md) | [33.2 d](/filings/0001558370-25-003544.md) | [35.2](/filings/0001558370-25-007571.md) | [40.4](/filings/0001558370-25-011307.md) | [34.3](/filings/0001558370-24-015532.md) | [39.1 d](/filings/0001558370-25-003544.md) | [28.9](/filings/0001558370-25-007571.md) | [23.0](/filings/0001558370-25-011307.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | [16.2](/filings/0001558370-24-015532.md) | [16.9 d](/filings/0001558370-25-003544.md) | [19.7](/filings/0001558370-25-007571.md) | [19.1](/filings/0001558370-25-011307.md) | [21.3](/filings/0001558370-24-015532.md) | [27.2 d](/filings/0001558370-25-003544.md) | [23.3](/filings/0001558370-25-007571.md) | [18.5](/filings/0001558370-25-011307.md) |
| Operating income | $m | [(43.0)](/filings/0001558370-23-018265.md) | [(27.2) d](/filings/0001558370-25-003544.md) | [1.7](/filings/0001558370-24-008287.md) | [(44.9)](/filings/0001558370-24-011798.md) | [(46.6)](/filings/0001558370-24-015532.md) | [(49.9) d](/filings/0001558370-25-003544.md) | [(49.3)](/filings/0001558370-25-007571.md) | [68.7](/filings/0001558370-25-011307.md) | [(14.7)](/filings/0001558370-24-015532.md) | [(73.5) d](/filings/0001558370-25-003544.md) | [(45.7)](/filings/0001558370-25-007571.md) | [(30.3)](/filings/0001558370-25-011307.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.5](/filings/0001558370-25-011307.md) | [1.1](/filings/0001558370-24-015532.md) | [1.7 d](/filings/0001558370-25-003544.md) | [1.9](/filings/0001558370-25-007571.md) | [1.0](/filings/0001558370-25-011307.md) |
| Income tax | $m | [0.4](/filings/0001558370-23-018265.md) | [1.0 d](/filings/0001558370-25-003544.md) | [0.6](/filings/0001558370-24-008287.md) | [0.7](/filings/0001558370-24-011798.md) | [0.7](/filings/0001558370-24-015532.md) | [(0.7) d](/filings/0001558370-25-003544.md) | [0.5](/filings/0001558370-25-007571.md) | [0.5](/filings/0001558370-25-011307.md) | [0.8](/filings/0001558370-24-015532.md) | [1.7 d](/filings/0001558370-25-003544.md) | [0.6](/filings/0001558370-25-007571.md) | [0.6](/filings/0001558370-25-011307.md) |
| Net income | $m | [(41.4)](/filings/0001558370-23-018265.md) | [(29.3) d](/filings/0001558370-25-003544.md) | [1.0](/filings/0001558370-24-015532.md) | [(21.4)](/filings/0001558370-24-015532.md) | [(45.6)](/filings/0001558370-24-015532.md) | [(47.9) d](/filings/0001558370-25-003544.md) | [(48.5)](/filings/0001558370-25-011307.md) | [69.5](/filings/0001558370-25-011307.md) | [(17.6)](/filings/0001558370-24-015532.md) | [(74.2) d](/filings/0001558370-25-003544.md) | [(47.6)](/filings/0001558370-25-011307.md) | [(30.3)](/filings/0001558370-25-011307.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001558370-23-018265.md) | not reported | [0.00](/filings/0001558370-24-008287.md) | [(0.02)](/filings/0001558370-24-011798.md) | [(0.03)](/filings/0001558370-24-015532.md) | not reported | [(0.03)](/filings/0001558370-25-007571.md) | [0.04](/filings/0001558370-25-011307.md) | [(0.01)](/filings/0001558370-24-015532.md) | not reported | [(0.03)](/filings/0001558370-25-007571.md) | [(0.02)](/filings/0001558370-25-011307.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0001558370-23-018265.md) | not reported | [0.00](/filings/0001558370-24-008287.md) | [(0.02)](/filings/0001558370-24-011798.md) | [(0.03)](/filings/0001558370-24-015532.md) | not reported | [(0.03)](/filings/0001558370-25-007571.md) | [0.05](/filings/0001558370-25-011307.md) | [(0.01)](/filings/0001558370-24-015532.md) | not reported | [(0.03)](/filings/0001558370-25-007571.md) | [(0.02)](/filings/0001558370-25-011307.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2022 (2022-09-30) | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [79.0](/filings/0001558370-22-016869.md) | [108](/filings/0001558370-24-002537.md) | [120](/filings/0001558370-23-009595.md) | [77.0](/filings/0001558370-23-014250.md) | [90.1](/filings/0001558370-23-018265.md) | [144](/filings/0001558370-25-003544.md) | [141](/filings/0001558370-24-008287.md) | [212](/filings/0001558370-24-011798.md) | [117](/filings/0001558370-24-015532.md) | [91.1](/filings/0001558370-25-011307.md) | [41.1](/filings/0001558370-25-007571.md) | [26.1](/filings/0001558370-25-011307.md) |
| Current assets | $m | [264](/filings/0001558370-22-016869.md) | [255](/filings/0001558370-24-002537.md) | [214](/filings/0001558370-23-009595.md) | [262](/filings/0001558370-23-014250.md) | [219](/filings/0001558370-23-018265.md) | [208](/filings/0001558370-25-003544.md) | [187](/filings/0001558370-24-008287.md) | [254](/filings/0001558370-24-011798.md) | [244](/filings/0001558370-24-015532.md) | [188](/filings/0001558370-25-011307.md) | [103](/filings/0001558370-25-007571.md) | [78.1](/filings/0001558370-25-011307.md) |
| Total assets | $m | [332](/filings/0001558370-22-016869.md) | [329](/filings/0001558370-24-002537.md) | [288](/filings/0001558370-23-009595.md) | [343](/filings/0001558370-23-014250.md) | [297](/filings/0001558370-23-018265.md) | [283](/filings/0001558370-25-003544.md) | [258](/filings/0001558370-24-008287.md) | [322](/filings/0001558370-24-011798.md) | [317](/filings/0001558370-24-015532.md) | [246](/filings/0001558370-25-011307.md) | [158](/filings/0001558370-25-007571.md) | [131](/filings/0001558370-25-011307.md) |
| Current liabilities | $m | [66.1](/filings/0001558370-22-016869.md) | [64.5](/filings/0001558370-24-002537.md) | [63.6](/filings/0001558370-23-009595.md) | [76.1](/filings/0001558370-23-014250.md) | [75.1](/filings/0001558370-23-018265.md) | [72.8](/filings/0001558370-25-003544.md) | [66.4](/filings/0001558370-24-008287.md) | [82.1](/filings/0001558370-24-011798.md) | [63.5](/filings/0001558370-24-015532.md) | [64.5](/filings/0001558370-25-011307.md) | [51.1](/filings/0001558370-25-007571.md) | [51.5](/filings/0001558370-25-011307.md) |
| Total liabilities | $m | [219](/filings/0001558370-22-016869.md) | [247](/filings/0001558370-24-002537.md) | [204](/filings/0001558370-23-009595.md) | [216](/filings/0001558370-23-014250.md) | [209](/filings/0001558370-23-018265.md) | [243](/filings/0001558370-25-003544.md) | [234](/filings/0001558370-24-008287.md) | [225](/filings/0001558370-24-011798.md) | [237](/filings/0001558370-24-015532.md) | [234](/filings/0001558370-25-011307.md) | [196](/filings/0001558370-25-007571.md) | [202](/filings/0001558370-25-011307.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [25.0](/filings/0001558370-24-011798.md) | [49.9](/filings/0001558370-24-015532.md) | [50.2](/filings/0001558370-25-011307.md) | [25.4](/filings/0001558370-25-007571.md) | [25.7](/filings/0001558370-25-011307.md) |
| Shareholders' equity | $m | [113](/filings/0001558370-23-018265.md) | [81.9](/filings/0001558370-25-003544.md) | [83.9](/filings/0001558370-24-015532.md) | [127](/filings/0001558370-24-015532.md) | [88.1](/filings/0001558370-24-015532.md) | [39.5](/filings/0001558370-25-011307.md) | [24.4](/filings/0001558370-25-011307.md) | [96.3](/filings/0001558370-25-011307.md) | [80.0](/filings/0001558370-24-015532.md) | [11.8](/filings/0001558370-25-011307.md) | [(37.4)](/filings/0001558370-25-011307.md) | [(71.0)](/filings/0001558370-25-011307.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(48.2) d](/filings/0001558370-23-018265.md) | [2.0 d](/filings/0001558370-25-003544.md) | [(37.3)](/filings/0001558370-24-008287.md) | [(43.8) d](/filings/0001558370-24-011798.md) | [(45.2) d](/filings/0001558370-24-015532.md) | [(14.7) d](/filings/0001558370-25-003544.md) | [(32.0)](/filings/0001558370-25-007571.md) | [47.4 d](/filings/0001558370-25-011307.md) | [(54.5) d](/filings/0001558370-24-015532.md) | [(34.2) d](/filings/0001558370-25-003544.md) | [(66.6)](/filings/0001558370-25-007571.md) | [(34.8) d](/filings/0001558370-25-011307.md) |
| Capital expenditure | $m | [10.0 d](/filings/0001558370-23-018265.md) | [3.4 d](/filings/0001558370-25-003544.md) | [2.3](/filings/0001558370-24-008287.md) | [1.2 d](/filings/0001558370-24-011798.md) | [0.3 d](/filings/0001558370-24-015532.md) | [0.8 d](/filings/0001558370-25-003544.md) | [0.1](/filings/0001558370-25-007571.md) | [0.4 d](/filings/0001558370-25-011307.md) | [0.1 d](/filings/0001558370-24-015532.md) | [0.2 d](/filings/0001558370-25-003544.md) | [1.2](/filings/0001558370-25-007571.md) | [0.1 d](/filings/0001558370-25-011307.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [937](/filings/0001558370-22-016869.md) | [940](/filings/0001558370-23-009595.md) | [963](/filings/0001558370-23-014250.md) | [981](/filings/0001558370-23-018265.md) | [1,000](/filings/0001558370-24-008287.md) | [1,108](/filings/0001558370-24-011798.md) | [1,358](/filings/0001558370-24-015532.md) | [1,451](/filings/0001558370-25-007571.md) | [1,559](/filings/0001558370-25-011307.md) | [1,535](/filings/0001558370-24-015532.md) | [1,542](/filings/0001558370-25-007571.md) | [1,585](/filings/0001558370-25-011307.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,590,309,546 at 2025-08-11, from the cover of the [10-Q filed 2025-08-13](/filings/0001558370-25-011307.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.